Skip to main content


Swipe om te navigeren naar een ander artikel

02-05-2018 | Original Article - E‑Learning | Uitgave 6/2018 Open Access

Netherlands Heart Journal 6/2018

Optimal long-term antithrombotic management of atrial fibrillation: life cycle management

Netherlands Heart Journal > Uitgave 6/2018
R. Pisters, A. Elvan, H. J. G. M. Crijns, M. E. W. Hemels


Optimal antithrombotic management of atrial fibrillation equals balancing between prevention of arterial thromboembolism, predominantly ischaemic stroke, and haemorrhagic complications. Over time different antithrombotic agents and strategies have been developed. At present, non-vitamin K antagonist oral anticoagulants (NOACs) are the first-line therapy for stroke prevention in patients with non-valvular atrial fibrillation (i.e. without a mechanical valve prosthesis or rheumatic heart disease). Considering the impact of the suboptimal adoption of recommended oral anticoagulant therapy, as experienced with the previous first-line vitamin K antagonists, this review focuses on adequate use of NOACs. As such, we address the most important and clinically challenging issues in the antithrombotic life cycle management for long-term stroke prevention in atrial fibrillation.

Onze productaanbevelingen

Netherlands Heart Journal

Het Netherlands Heart Journal wordt uitgegeven in samenwerking met de Nederlandse Vereniging voor Cardiologie en de Nederlandse Hartstichting. Het tijdschrift is Engelstalig en wordt gratis beschikbaa ...

Over dit artikel

Andere artikelen Uitgave 6/2018

Netherlands Heart Journal 6/2018 Naar de uitgave